Blood, volume 129, issue 4, pages 424-447
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
Hartmut Döhner
1
,
Elihu Estey
2
,
David Grimwade
3
,
Sergio Amadori
4
,
Frederick R. Appelbaum
2
,
Thomas Buchner
5
,
Hervé Dombret
6
,
Benjamin L. Ebert
7
,
Pierre Fenaux
8
,
Richard A. Larson
9
,
Ross L Levine
10
,
Francesco Lo-Coco
4
,
Tomoki NAOE
11
,
Dietger Niederwieser
12
,
Gert J Ossenkoppele
13
,
Miguel Sanz
14
,
Jorge Sierra
15
,
Martin S. Tallman
10
,
Hwei-Fang Tien
16
,
Andrew H. Wei
17, 18
,
Bob Löwenberg
19
,
Clara D Bloomfield
20
6
Institut Universitaire d’Hématologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France;
|
8
Service d’Hématologie, Hôpital Saint-Louis, Paris, France;
|
10
11
National Hospital Organization Nagoya Medical Center, Nagoya, Japan;
|
13
15
Hematology Department, Hospital de la Santa Creu i Sant Pau, Jose Carreras Leukemia Research Institute, Barcelona, Spain;
|
Publication type: Journal Article
Publication date: 2017-01-26
PubMed ID:
27895058
Biochemistry
Cell Biology
Immunology
Hematology
Abstract
The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.
Found
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.